-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 23, Puli Pharmaceutical announced that the company has recently received the marketing authorization of pantoprazole sodium for injection issued by the British MHRA, and the indications are gastric and duodenal ulcers, reflux esophagitis; Zorin.
Pantoprazole sodium for injection is a selective long-acting proton pump inhibitor.
Pantoprazole sodium for injection was approved and marketed in the United States in March 2001 by Wyeth Company (authorized by Takeda), the trade name is PROTONIX, the dosage form is injection, and the specification is 40mg
After the company successfully developed the generic drug of pantoprazole sodium for injection, it has successively submitted registration applications in many countries at home and abroad